"New England Cancer Specialists is a physician-owned, patient-centered medical practice, recognized as a leader in cancer patient care, treatment, and research. With nearly half of Maine’s medical oncologists and hematologists on our team, we are the region’s largest oncology group, serving people in need throughout New England."

During the past decade, New England Cancer Specialists conducted 36 clinical trials. In the 10-year time frame, 36 clinical trials started and 20 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 13 clinical trials were completed. i.e. 92.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New England Cancer Specialists" #1 sponsor was "Hoffmann-La Roche" with 17 trials, followed by "Eli Lilly and Company" with 5 trials sponsored, "Alliance Foundation Trials, LLC." with 4 trials sponsored, "Genentech, Inc." with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New England Cancer Specialists" #1 collaborator was "Genentech, Inc." with 3 trials as a collaborator, "NSABP Foundation Inc" with 3 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "German Breast Group" with 2 trials as a collaborator and "Pfizer" with 2 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "New England Cancer Specialists" are "Breast Cancer" (9 trials), "Non-Small Cell Lung Cancer" (4 trials), "Breast Neoplasms" (3 trials), "Neoplasm Metastasis" (3 trials) and "Cancer" (2 trials). Many other conditions were trialed in "New England Cancer Specialists" in a lesser frequency.

Most popular intervention types in "New England Cancer Specialists" are "Drug" (41 trials), "Biological" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (10 trials), "Docetaxel" (9 trials), "Placebo" (9 trials), "Carboplatin" (8 trials) and "Paclitaxel" (6 trials). Other intervention names were less common.

The vast majority of trials in "New England Cancer Specialists" are 38 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "New England Cancer Specialists". undefined are not yet recruiting, 8 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 18 completed trials in New England Cancer Specialists, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in New England Cancer Specialists, 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".